ALMSHIGH SIGNALFINANCIAL10-K

ALMS completed its acquisition of ACELYRIN, significantly expanding its share count and operations while burning through substantial cash amid meaningfully higher operating losses.

The merger fundamentally transformed ALMS's capital structure, with voting shares increasing from 47.2M to 123.1M shares, indicating significant dilution for existing shareholders. The company's cash position declined nearly 50% to $89.7M while operating cash flow deteriorated substantially, raising concerns about runway duration given the current burn rate.

Comparing 2026-03-19 vs 2025-03-19View on EDGAR →
FINANCIAL ANALYSIS

ALMS shows the financial profile of a post-acquisition biotech with significantly expanded operations and correspondingly higher cash burn. R&D expenses grew meaningfully to $386.0M, driving operating losses substantially higher, while operating cash flow deteriorated to -$369.5M. Despite the challenging cash flow dynamics, total assets increased 20.8% and stockholders' equity grew 15.8%, reflecting the value brought in through the ACELYRIN acquisition, though the company's cash runway has shortened considerably.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-62.3%
$1.7M→$653K

Capex reduced 62.3% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Income
P&L
-50.9%
-$300.8M→-$453.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Cash & Equivalents
Balance Sheet
-47.1%
$169.5M→$89.7M

Cash declined 47.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

R&D Expense
P&L
+45.4%
$265.6M→$386.0M

R&D investment increased 45.4% — signals commitment to future product development, though near-term margin impact.

Operating Cash Flow
Cash Flow
-44.9%
-$255.1M→-$369.5M

Operating cash flow fell 44.9% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
+44%
$50.9M→$73.3M

Current liabilities surged 44% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+36.8%
$80.9M→$110.6M

Liabilities grew 36.8% — significant increase in debt or obligations, assess impact on financial flexibility.

Total Assets
Balance Sheet
+20.8%
$341.0M→$411.9M

Asset base grew 20.8% — expansion through organic growth, acquisitions, or capital deployment.

Net Income
P&L
+17.3%
-$294.2M→-$243.3M

Net income grew 17.3% — bottom-line growth signals improving overall business health.

Stockholders Equity
Balance Sheet
+15.8%
$260.1M→$301.3M

Equity base grew 15.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-19
ADDED
As of March 12, 2026, the registrant had 123,139,425 shares of voting common stock, $0.0001 par value per share, and 4,059,908 shares of non-voting common stock, $0.0001 par value per share, outstanding.
Additional discussion of the risks summarized in this Risk Factors Summary, and other risks that we face, can be found below under the heading Risk Factors under Part I, Item 1A of this Annual Report on Form 10-K and should be carefully considered, together with other information in this Annual Report on Form 10-K, before making investment decisions regarding our securities.
Our clinical trials may reveal serious adverse events ( SAEs ) and significant adverse events ( AEs ) not seen in our preclinical studies or prior clinical trials and may result in a safety or tolerability profile that could delay or prevent regulatory approval or market acceptance of envudeucitinib (or envu ), formerly known as ESK-001, A-005 or any future product candidates.
We are subject to various risks related to the acquisition and integration of ACELYRIN (as defined herein).
Food and Drug Administration (the FDA ) and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
+7 more — sign up free →
REMOVED
As of March 12, 2025, the registrant had 47,222,419 shares of voting common stock, $0.0001 par value per share, and 7,184,908 shares of non-voting common stock, $0.0001 par value per share, outstanding.
If such Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Form 10-K, such information will be included in an amendment to this Form 10-K to be filed within such 120-day period.
Additional discussion of the risks summarized in this Risk Factors Summary, and other risks that we face, can be found below under the heading Risk Factors under Part I, Item 1A.
of this Annual Report on Form 10-K and should be carefully considered, together with other information in this Annual Report on Form 10-K, before making investment decisions regarding our securities.
The Merger (as defined herein) may not be completed on the terms or timeline currently contemplated, or at all.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →